Launch of - stirling pharma

STIRLING PRODUCTS TO LAUNCH GENERIC PHARMACY RANGE
FOR IMMEDIATE RELEASE
23 December 2009
• “Stirling Pharma” to launch in Australia in March 2010 • National Australian Sales Representation in Place • Establishment of Relationship with Major International Pharma
Australian healthcare company Stirling Products Limited (ASX:STI) advises that the Company has
agreed to and established a working relationship with Cipla Limited, a major international
pharmaceutical drug manufacturer based in India. The Company’s business initiatives with Cipla
have commenced and will be the subject of formal Memorandums of Understanding that are
expected to be entered into as the relationship progresses and as the Company continues to
expand its reach and influence.
Cipla, which exports to over 183 countries, has been a forerunner of the provisioning of affordable
drugs to India as well as to many developing countries that in most cases have significant public
health burdens from diseases such as AIDS, TB, typhoid, malaria and dengue fever. Cipla has
singularly been responsible for the dramatic reduction in the cost of AIDS treatments reducing cost
to patients from $12,000 plus per annum to a current $150 -250. See: www.cipla.com
In its current trial initiatives for AIDS and TB, the Company will where applicable preferentially use
the Cipla drug products as Cipla is the world’s largest supplier of AIDS drugs as well as a
substantial supplier of TB drugs. Cipla also manufactures and distributes a full range of products
including: antibiotics, anti-bacterials, anti-asthmatics, anthelmintics, anti-ulcerants, oncology,
corticosteroids, nutritional supplements and cardiovascular drugs.
Cipla will also be the Company’s preferred supplier of R-salbutamol in all of its further trial work and
ultimate commercial products for both animal and human applications.

Stirling Pharma

The Company is pleased to further advise that it is launching a broad range of OTC and generic
prescription drugs under the “Stirling Pharma” brand to pharmacies throughout Australia. The
Company proposes to launch “Stirling Pharma” on the Gold Coast during Australia’s largest
Pharmacy industry event, the Australian Professional Pharmacy Conference, in March 2010.
Following establishment of “Stirling Pharma” in Australia, the Company will seek to expand “Stirling
Pharma” selectively and progressively in other global regions.
ABN 32 077 105 429
Level 1, 275 George Street, Sydney, NSW Australia
Tel: +61 2 9299 9270 Fax: +61 2 9299 9276
The “Stirling Pharma” offering to the national pharmacy market in Australia will be supplemented
with the Company’s botanical products and will be marketed throughout the Country by a proven
national pharmaceutical marketing team, led by one of the industry’s top Sales Directors that have
all agreed to commence employment with “Stirling Pharma” as of late February 2010.
The “Stirling Pharma” initiative contributes further and substantially to the Company’s strategy of its
development as an emerging FIPCO (Fully Integrated Pharma Company) without dependence upon
any particular single product or activity.
For further information see: www.stirlingproducts.net or contact
Peter Boonen
Managing Director
Stirling Products Limited
Ph: +61 2 9299 9270
E: [email protected]

Investor Relations inquiries please contact:
James Moses
Mandate Corporate
Ph: +61 420 991 574
E: [email protected]
ABN 32 077 105 429
Level 1, 275 George Street, Sydney, NSW Australia
Tel: +61 2 9299 9270 Fax: +61 2 9299 9276

Source: http://genera.proactiveinvestors.com.au/genera/genera/webroot/files/sponsor_files/stirling_pharma_press_release_20091223.pdf